Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01913171
Other study ID # HULA 233401
Secondary ID HULA233401
Status Completed
Phase N/A
First received June 18, 2013
Last updated July 30, 2013
Start date November 2011
Est. completion date March 2012

Study information

Verified date July 2013
Source Helsinki University
Contact n/a
Is FDA regulated No
Health authority Finland: University of Helsinki / Department of internal medisine / Devision of diabetes
Study type Interventional

Clinical Trial Summary

o determine effects of hula-hooping on android obesity, metabolic parameters and adipose tissue (AT) gene expression.


Recruitment information / eligibility

Status Completed
Enrollment 53
Est. completion date March 2012
Est. primary completion date March 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- age between 18 and 70 years

- central adiposity as measured by the waist circumference (>80 cm in females and >94 cm in males) (9)

- ability to hula-hoop for a minimum of 2 minutes and to have the necessary space available for this activity either at home or at work

- ability to communicate meaningfully with the investigator and legal competence to provide written informed consent

Exclusion Criteria:

- clinical or biochemical evidence of disease other than obesity as judged by history, physical examination and standard laboratory tests

- excessive use of alcohol, i.e., over 20 g/day

- use of medications known to affect glucose or lipid metabolism and

- pregnancy or lactation

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label


Related Conditions & MeSH terms

  • Android Obesity, Metabolic Parameters and Adipose Tissue (AT) Gene Expression

Intervention

Other:
Exercise


Locations

Country Name City State
Finland Department of Medicine, University of Helsinki Helsinki

Sponsors (1)

Lead Sponsor Collaborator
Helsinki University

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Other adipose tissue inflammation To determine the effects of HULA compared to WALK on adipose tissue inflammation, a needle aspiration biopsy of abdominal s.c. adipose tissue was taken under local anesthesia with lidocaine before and after each exercise intervention. The adipose tissue sample was immediately frozen in liquid nitrogen and then stored at -80°C until analysis. Total RNA from s.c. AT was isolated.Relative quantification for the genes of interest (see list below) was carried out using normalization to the 36B4 and ß-actin mRNA values.
ABCA1 Adiponectin ANGPTL8 CHOP CD4 CD8 CD68 ETFDH FOXP3 GLUT4 MCP-1 MRC-1 PGC-1a VEGF-A ß-actin
6weeks Yes
Primary Android obesity The primary objective was to evaluate the change in the % fat in the android region as measured by DEXA during 6 weeks of HULA as compared to WALK 6weeks Yes
Secondary metabolic parameters The secondary objectives included the comparison of differences in waist circumference (cm), relative and absolute trunk and limb muscle mass as measured by DEXA (% and kg), fasting plasma glucose (mmol/l), fasting serum insulin (mU/l), liver enzymes (U/l), fasting plasma LDL and HDL cholesterol and triglycerides (mmol/l). Gene expression was analyzed in adipose tissue biopsies collected before and after each exercise intervention. 6weeks Yes